SmallCapFirm

Afternoon Update: Key Details To Know About NYSE American Profile (ATNM)

February 21st

SCF Readers,

There's no way around it. It's a bloodbath out there today.

The Dow... The Nasdaq... The NYSE...

Everywhere you look, it's red. But here's why that shouldn't stop you from keeping ATNM high on your watch-list near term.

The company is coming off incredible news over the weekend. Check it out here: Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

Plus, Barchart continues to report a multitude (over 10) triggered technicals across the short, medium, and long term.

Don't forget what we found over at MarketBeat. Multiple analyst targets (including one from HC Wainwright of $53) provide ATNM with a ton of potential upside from current trading levels.

Long story short, even though we're swimming in a sea of red today, ATNM needs to continue to be researched moving forward.

If there are any more updates, I'll have them out to you quickly.

-----

Back on radar, here's a past champ profile riding a red hot chart in 2023.

When I brought this profile to your attention back in 2022, it absolutely erupted.

During its chart-shattering, vertical surge, it became a multi-dollar mover in just a handful of days.

Its approximate 40+% move showed how explosive this breakout idea can be in a short amount of time.

But now it's 2023. And it's time to get it back on radar again.

Here's why...

Over the weekend, the company made a huge announcement in regards to "positive results" that could become a game-changing catalyst going into Tuesday's opening bell.

On top of that, Barchart is reporting 10+ bullish technical indicators across the short, medium, and long term.

And with it trading above 3 key potential lines of support, having a float of fewer than 25Mn shares, and having a $53 analyst target, this past champ needs immediate attention.

For Tuesday, February 21st, there is only one profile NYSE American breakout idea to have at the top of your watch-list:

*Actinium Pharmaceuticals, Inc. (ATNM)*

Actinium Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing targeted radiotherapies to deliver cancer-killing radiation with cellular level precision to treat patients with high unmet needs.

And ATNM has multiple potential catalysts to pay attention to right now. Check them out:

No. 1 - Could Saturday's "Positive Results" Announcement Fuel ATNM To A Near Term Breakout?

No. 2 - Bullish Triggered Technicals Galore

No. 3 - ATNM Has Strong Analyst Coverage Including A Massive HC Wainwright $53 Target

No. 4 - New Partnership With The NCI Could Prove Extremely Fruitful Long Term

No. 5 - Low Float Volatility Possible On Daily Basis

But more on those in a second...

There is Demand For a Leukemia Cure... and the Market Looks Lucrative

The leukemia therapeutics market could reach $17.1Bn by 2024 from $12.3Bn in 2019, at a CAGR of 6.8%.

Do you know what’s driving this market?

A rising prevalence of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). The increasing number of approvals of novel & innovative dr-ugs and immunotherapies is evidence of an increasing need for leukemia therapies.

Say hello to a wide-open opp. for Actinium Pharmaceuticals (ATNM).

Treatment options for AML, or acute myeloid leukemia, is precisely an unmet need- especially for those under 45. According to Eunice Wang, MD, Chief of the Leukemia Service at Roswell Park Comprehensive Cancer Center, as quoted by Check Rare, it is rarely diagnosed in patients under the age of 45. (1)

At the moment, the five-year survival rate for those 20 and older is also putrid 26%. (2)

Some must also contend with relapsed, or recurrent, acute myelogenous leukemia (AML), which means leukemia came back after treatment and after reaching remission. Refractory AML means leukemia did not respond to treatment. Complete remission can’t be achieved because chemotherapy wasn’t able to kill off enough leukemia cells. (3)

ATNM's Differentiated Targeted Radiotherapy Pipeline

First-in-class and best-in-class potential for clinical assets Iomab-B and Actimab-A with recent positive clinical data supporting continued advancement of programs:

A Few Of ATNM's Company Highlights

• Actinium has delivered positive clinical data from Iomab-B and Actimab-A that set the stage to build a fully integrated specialty oncology company built on our innovative R&D capabilities
• Positive top-line results from the pivotal Phase 3 SIERRA trial p<0.0001 for primary endpoint durable Complete Remission
• Iomab-B addresses initial market of 10,000 r/r AML patients who do not access potentially curative BMT with current approaches

Expected Value Creating Milestones

Grab the full company presentation here.

-----

And as I mentioned above ATNM has 5 potential catalysts to know right now. Here they are:

No. 1 ATNM Potential Catalyst - Could Saturday's "Positive Results" Announcement Fuel ATNM To A Near Term Breakout?

Actinium Announces Positive Full Data Results From the Pivotal Phase 3 SIERRA Trial in Patients with Active, Relapsed or Refractory Acute Myeloid Leukemia

NEW YORK, Feb. 18, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced positive results for the primary and secondary endpoints from its pivotal Phase 3 SIERRA trial of Iomab-B in patients age 55 and above with active relapsed or refractory acute myeloid leukemia (r/r AML). Iomab-B met the primary endpoint of durable Complete Remission (dCR) of 6-months following initial complete remission following BMT with a high degree of statistical significance (p<0.0001). Additionally, Iomab-B produced a significant and clinically meaningful improvement in the secondary endpoint of Event-Free Survival (EFS), with a 78% reduction in the probability of an event (Hazard Ratio=0.22, p<0.0001). Iomab-B doubled 1-year survival compared to the control arm excluding cross over patients (26.1% vs 13.1%) as well as median overall survival (6.4 months vs. 3.2 months). Iomab-B was well tolerated with four times lower rates of sepsis (6.1% vs 28.6%) and lower rates of febrile neutropenia, mucositis and acute graph versus host disease (aGVHD). Iomab-B enabled unprecedented access to BMT with 100% engraftment in patients receiving a therapeutic dose of Iomab-B compared to 18% of patients in the control arm and Iomab-B produced a 75% post-BMT Complete Remission (CR) rate compared to 6.3% post-BMT CR in the control arm. These high rates of access and post-BMT CR enabled the highly significant primary endpoint results. The full SIERRA results were presented in the late-breaker session at the 2023 Tandem Meetings: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood & Marrow Transplant Research (CIBMTR).

...

Read the full article here.

-----

No. 2 ATNM Potential Catalyst - Bullish Triggered Technicals Galore

I'm telling you right now... Don't discount ATNM's technical indicators.

At close on Friday, ATNM was displaying several triggered technical indicators across the short, medium term, and long term.

Barchart was reporting these technical indicators as triggered:

Short Term Indicators

• 20 Day Moving Average
• 20 - 50 Day MACD Oscillator
• 20 - 100 Day MACD Oscillator
• 20 - 200 Day MACD Oscillator

Medium Term Indicators

• 50 Day Moving Average
• 50 - 100 Day MACD Oscillator
• 50 - 150 Day MACD Oscillator
• 50 - 200 Day MACD Oscillator

Long Term Indicators

• 100 Day Moving Average
• 150 Day Moving Average
• 200 Day Moving Average
• 100 - 200 Day MACD Oscillator

The website also shares its all-important "Trend Seeker" composite indicator is triggered too.

Could this be a signal that ATNM is only starting to heat up after a recent green move last week?

-----

No. 3 ATNM Potential Catalyst - ATNM Has Strong Analyst Coverage Including A Massive HC Wainwright $53 Target

Analyst coverage on ATNM is at a premium right now.

Check it out:

(Source)

Each brokerage/analyst has given ATNM a target significantly higher than this NYSE American past champ closed this past Friday.

At the tippy top, according to MarketBeat, is an HC Wainwright target of $53.00.

From this past Friday's close, that provides ATNM with an incredible upside potential in the neighborhood of 285%.

After Saturday's huge "positive results" announcement, could some of these analysts upgrade their targets in the near term?

-----

No. 4 ATNM Potential Catalyst - New Partnership With The NCI Could Prove Extremely Fruitful Long Term

Actinium Signs Cooperative Research and Development Agreement with National Cancer Institute to Further Enhance Clinical and Non-clinical Development of Actimab-A for the Treatment of Acute Myeloid Leukemia and Other Hematologic Malignancies

- National Cancer Institute will sponsor and oversee clinical trials of Actimab-A under the terms of the Cooperative Research and Development Agreement

- Collaboration will provide Actimab-A and other necessary support to study Actimab-A alone or in combinations with chemotherapy, immunotherapy and/or targeted agents aligned with Actinium's development strategy

- Over 2,000 institutions within NCI funded extramural clinical networks will have access to Actimab-A for conducting clinical and non-clinical research and development

- CRADA Clinical Studies will be performed utilizing NCI's Experimental Therapeutics Clinical Trials Network (ETCTN) and National Clinical Trials Network (NCTN)

NEW YORK, Feb. 6, 2023 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes for Health (NIH), to develop Actimab-A for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. Under the terms of the CRADA, the NCI will serve as the regulatory sponsor for any clinical trials mutually approved by both parties to study Actimab-A while Actinium will be responsible for supplying and distributing Actimab-A to participating clinical sites and providing additional support as needed. The CRADA will provide broad support for the development of Actimab-A alone or in combination with chemotherapy, immunotherapy, targeted agents and other novel combinations, in line with Actinium's strategy of leveraging Actimab-A's targeted radiotherapy mechanism to elicit synergistic effects.

...

Read the full article here.

-----

No. 5 ATNM Potential Catalyst - Low Float Volatility Possible On Daily Basis

According to the Yahoo Finance website, ATNM has a low float.

The website reports this profile to have approximately 24.47Mn shares in its float.

Why is that important? It's important on one crucial level. Volatility.

Could more 2023 positive company news help provide a near term spark?

-----

ATNM Recap - 5 Potential Catalysts Could Provide A Near Term Breakout Spark

No. 1 - Could Saturday's "Positive Results" Announcement Fuel ATNM To A Near Term Breakout?

No. 2 - Bullish Triggered Technicals Galore

No. 3 - ATNM Has Strong Analyst Coverage Including A Massive HC Wainwright $53 Target

No. 4 - New Partnership With The NCI Could Prove Extremely Fruitful Long Term

No. 5 - Low Float Volatility Possible On Daily Basis

-----

Coverage is officially reinitiated on ATNM. When time permits, do this:

Get ATNM on your radar now.

Sincerely,

Axel Adams

Editor, SCF

Source 1
Source 2
Source 3

(Always Remember The St-ock Prices Could Be Significantly Lower Now From The Dates I Provided.)​